Li Yuan, Song Lihua
Department of Internal Medicine, Shandong Tumor Hospital, Shandong Academy of Medical Sciences Jinan 250117, China.
Zhongguo Fei Ai Za Zhi. 2012 Feb;15(2):106-11. doi: 10.3779/j.issn.1009-3419.2012.02.08.
With a greater understanding of tumor biology, novel molecular-targeted strategies that block cancer progression pathways have been evaluated as a new therapeutic approach for treating non-small cell lung cancer (NSCLC). Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, show favorable response to EGFR mutant lung cancer in some populations of NSCLC patients. However, the efficacy of EGFR-TKIs is limited by either primary (de novo) or acquired resistance after therapy. This review will focus on recently identified mechanisms of primary and acquired resistance to EGFR TKIs and strategies currently being employed to overcome resistance.
随着对肿瘤生物学的深入了解，阻断癌症进展途径的新型分子靶向策略已被评估为治疗非小细胞肺癌（NSCLC）的一种新的治疗方法。表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKIs），如吉非替尼和厄洛替尼，在部分非小细胞肺癌患者群体中对EGFR突变型肺癌显示出良好的反应。然而，EGFR-TKIs的疗效受到治疗后原发性（从头）或获得性耐药的限制。本综述将聚焦于最近发现的对EGFR-TKIs原发性和获得性耐药的机制以及目前用于克服耐药的策略。
